Daxor Corporation (NASDAQ:DXR - Get Free Report) was the target of a large growth in short interest in March. As of March 13th, there was short interest totaling 9,006 shares, a growth of 149.8% from the February 26th total of 3,605 shares. Approximately 0.4% of the company's stock are short sold. Based on an average trading volume of 16,592 shares, the days-to-cover ratio is currently 0.5 days. Based on an average trading volume of 16,592 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.4% of the company's stock are short sold.
Daxor Stock Performance
Shares of DXR opened at $10.35 on Wednesday. The company has a 50 day moving average of $12.15 and a two-hundred day moving average of $12.68. Daxor has a twelve month low of $7.10 and a twelve month high of $14.76.
Wall Street Analysts Forecast Growth
Several research firms have recently commented on DXR. Weiss Ratings reissued a "hold (c)" rating on shares of Daxor in a research report on Monday, December 29th. Lake Street Capital assumed coverage on Daxor in a research note on Wednesday, February 11th. They issued a "buy" rating on the stock. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, Daxor has an average rating of "Moderate Buy".
View Our Latest Stock Report on Daxor
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Daxor stock. Osaic Holdings Inc. bought a new stake in shares of Daxor Corporation (NASDAQ:DXR - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 8,750 shares of the company's stock, valued at approximately $86,000. Osaic Holdings Inc. owned approximately 0.18% of Daxor at the end of the most recent reporting period. Institutional investors own 1.34% of the company's stock.
About Daxor
(
Get Free Report)
Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company's core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient's fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.
In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Daxor, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Daxor wasn't on the list.
While Daxor currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.